GNPX Projected Dividend Yield
Genprex Inc ( NASDAQ : GNPX )Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. Co.'s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. Co.'s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). 21 YEAR PERFORMANCE RESULTS |
GNPX Dividend History Detail GNPX Dividend News GNPX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |